Dana-Farber and Gustave Roussy to Host Fifth Transatlantic Oncology Exchange in March 2026

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on Friday, March 27, 2026, bringing together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research. The full-day meeting, held from 9 a.m. to 5 p.m. ET at Dana-Farber in Boston and livestreamed, continues a long-standing collaboration between Dana-Farber and Gustave Roussy in France, with support from L'Institut Servier and Medscape Medical Affairs.

Scientific discussions will focus on advances in epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming, with sessions spanning translational research through clinical application. The event will highlight emerging research and therapeutic approaches aimed at accelerating progress in cancer treatment worldwide.

The medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School will co-chair the meeting. "Our meetings connect the best minds in oncology across continents to share and discuss emerging trends and the latest innovations, from translational research to clinical care," the co-chair stated. "The goal is to help facilitate our shared aim — to cure cancer."

The lead for International Academic Partnerships and deputy director of the Department of Medical Oncology at Gustave Roussy emphasized the importance of global scientific collaboration. "Cancer knows no borders, and neither should innovation," the official said. "By bringing together bold ideas, diverse expertise, and a common purpose, this transatlantic partnership is advancing science and building hope for patients around the world."

The managing director of L'Institut Servier underscored the meeting's role in advancing cancer research through collaboration. "By bringing together leading experts from both sides of the Atlantic, we foster innovation and accelerate progress toward better outcomes for patients everywhere," the managing director said.

The vice president of Medscape Medical Affairs highlighted the organization's continued support of the initiative. "The Transatlantic Exchange is a project we are always honored to be part of," the vice president said. "Everyone involved is deeply committed to delivering educational programs that have a meaningful impact for participants and for the broader oncology community."

Previous meetings in the series have focused on cutting-edge topics, including immuno-oncology, artificial intelligence and data science in oncology, liquid biopsy, and radioligand therapies. The Fifth Transatlantic Exchange is free to attend and open to healthcare professionals with an interest in oncology, with in-person and virtual registration now open.